Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study

Emil Lou,Rachel Isaksson Vogel,Spencer Hoostal,Phillip Wong,A. Grad,Minnu Monu,Tomasz Lukaszewski,Jaai Deshpande,Elizabeth L. Dickson,Molly Klein,Michael A. Linden,Subree Subramanian,Deanna Teoh,Melissa A. Geller

Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study

2019

Emil Lou
Rachel Isaksson Vogel
Spencer Hoostal
Phillip Wong
A. Grad
Minnu Monu
Tomasz Lukaszewski
Jaai Deshpande
Elizabeth L. Dickson
Molly Klein
Michael A. Linden
Subree Subramanian
Deanna Teoh
Melissa A. Geller

Lesson Learned. Circulating tumor cells, microRNA markers, or other biomarkers merit examination as part of correlative scientific analyses in prospective clinical trials.

Keywords:

Pathology
Circulating tumor cell
Cancer research
Prospective cohort study
Biomarker (medicine)
microRNA
Ovarian carcinomas
Medicine
Antibody
Ovarian cancer
Clinical trial
Internal medicine
Oncology
ovarian carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations